Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- Or Panitumumab-Refractory Metastatic Colorectal Cancer

Journal of Clinical Oncology - United States
doi 10.1200/jco.2010.30.4154
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Cetuximab Plus Irinotecan Versus Panitumumab in Patients With Refractory Metastatic Colorectal Cancer in Ontario, Canada

International Journal of Cancer
Cancer ResearchOncology
2017English

Phase 1 Pharmacokinetic Study of MK-0646 (Dalotuzumab), an Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody, in Combination With Cetuximab and Irinotecan in Japanese Patients With Advanced Colorectal Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2013English

Magnetic Resonance Imaging as an Early Indicator of Clinical Outcome in Patients With Metastatic Colorectal Carcinoma Treated With Cetuximab or Panitumumab

Clinical Colorectal Cancer
OncologyGastroenterology
2013English

Cetuximab and Platinum-Based Chemoradio- Or Chemotherapy of Patients With Epidermal Growth Factor Receptor Expressing Adenoid Cystic Carcinoma: A Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
2013English

Cetuximab Retreatment in Patients With Metastatic Colorectal Cancer Who Exhibited a Clinical Benefit in Response to Prior Cetuximab: A Retrospective Study

Oncology Letters
Cancer ResearchOncology
2018English

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- And PIK3CA- Wild-Type Metastatic Colorectal Cancer: The AGITG Randomised Phase II ICECREAM Study

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy

Clinical Breast Cancer
Cancer ResearchOncology
2016English

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy